Lecanemab: Over 90% Tolerate Alzheimer's Treatment

A study involving 2,672 patients in Japan has demonstrated the safety of Lecanemab, a drug designed to slow Alzheimer's progression by removing amyloid beta from the brain. The findings, collected by Eisai and analyzed by researchers, indicate that over 90% of patients tolerated the treatment without severe side effects.

The research, which examined data up to early July of the previous year, found that serious adverse events were exceptionally rare, occurring in just 0.1% of patients. Mild symptoms like fever or headache were reported by 17% but resolved within days.

Overall, 7.3% of patients discontinued the Lecanemab treatment by the 28-week mark. Lead researcher Atsushi Iwata stated that these findings confirm the drug's safety in actual clinical practice. A longer follow-up study is planned to assess effectiveness over three years.